Facebook
Twitter
LinkedIn
Forward2024 Summit on Hematological Cancers
This CME-accredited activity 2024 Annual Summit on Hematologic Cancers features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances along with case-based discussion in the field of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.
Target Audience
- Cancer care professionals
- Practicing medical oncologists/hematologists
- Radiation oncologists
- Pathologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
ORGANIZING COMMITTEE
Course Director:
Binay Shah, MD, MHA - Binaytara Foundation
Co-Chairs:
Nitin Jain, MD- MD Anderson Cancer Center
Navneet Majhail, MD, MS- Sarah Cannon
Sonali Smith, MD- University of Chicago
Shaji Kumar, MD- Mayo Clinic
Hotel Information
Booking link coming soon...
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
- Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
- Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors
- Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies
GLOBAL ONCOLOGY PROJECT
Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/
DAY 1 – Friday, October 11, 2024
All times are listed in Central Daylight Time (CDT)
12:00 PM – 01:00 PM Registration, Exhibits, & Socialize
01:00 PM – 01:15 PM Opening Remarks
01:15 PM – 01:30 PM Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA
01:30 PM – 03:00 PM Session 1 - ALL
Chairs:
01:30 PM – 01:45 PM What have we learned from pediatric regimens in ALL? - Haydar Frangoul, MD, MS
01:45 PM – 02:00 PM CAR-T vs. Bispecifics Vs. Monoclonals in B-ALL
02:00 PM – 02:15 PM Treatment of Ph+/Ph-like ALL
02:15 PM – 03:00 PM Q & A and Case-Based Panel Discussion
03:00 PM – 03:30 PM Break & Exhibits
03:30 PM – 05:00 PM Session 2 - Aggressive Lymphomas
Chairs: Sairah Ahmed, MD
03:30 PM – 03:45 PM Updates in CAR-T therapy for aggressive lymphomas - Bhagirathbhai Dholaria, MD, MBBS
03:45 PM – 04:00 PM Focus on elderly patients with aggressive B-cell lymphomas - Sairah Ahmed, MD
04:00 PM – 04:15 PM Outpatient management of CAR-T therapy recipients - Jeremy Pantin, MD, FACP
04:15 PM – 05:00 PM Q & A and Case-Based Discussion
DAY 2 – Saturday, October 12, 2024
07:00 AM – 08:00 AM Registration, Exhibits & Socialize
08:30 AM – 10:00 AM Session 3 - Multiple Myeloma - Newly Dx
Chairs: Shaji Kumar, MD & Nisha Joseph, MD
08:30 AM – 08:45 AM Triplets or quadruplets – what is the right approach for newly diagnosed MM? - Nisha Joseph, MD
08:45 AM – 09:00 AM Transplant for MM – does it still have a role? - Natalie Callander, MD
09:00 AM – 09:15 AM Maintenance approaches for MM – one, two, or more drugs?
09:15 AM – 10:00 AM Q & A and Case-Based Discussion - Shuang Fu, MD, PhD; Jesus Berdeja, MD
10:00 AM – 10:30 AM Break & Exhibits
10:30 AM – 12:00 PM Session 4 - AML/MDS
Chairs: Stephen Strickland, MD, MSCI
10:30 AM – 10:45 AM Frontline Therapy of AML in 2024
10:45 AM – 11:00 AM Treatment options for relapsed/refractory AML Triplets in AML. Where are we and what’s next? - Naval Daver, MD
11.00 AM – 11.15 AM Venetoclax in AML/ALL. Which subsets and why? - Marina Konopleva, MD, PhD
11:15 AM – 11:30 AM Management of MDS after HMAs - Hetty Carraway, MD
11:30 AM – 12:00 PM Q & A and Case- Based Discussion - Somedeb Ball, MD, MBBS
12:00 PM – 01:00 PM Lunch, Exhibits, & Industry Sponsored Symposia
01:00 PM – 01:30 PM (Keynote) Evolution of ALL treatment for AYAs
01:30 PM – 03:00 PM Session 5 - CLL
Chairs: Nitin Jain, MD
01:30 PM – 01:45 PM BTK or BCL2i or Both for Frontline CLL - Danielle Brander, MD
01:45 PM – 02:00 PM Pirtobrutinib, CAR T, and others. How to incorporate it in practice?
02:00 PM – 02:15 PM Richter transformation. What’s new?
02:15 PM – 03:00 PM Q & A and Case-Based Discussion
03:00 PM – 03:30 PM Break & Exhibits
03:30 PM – 05:00 PM Session 6 - Low-Grade Lymphomas
Chairs: Sonali Smith, MD
03:30 PM – 03:45 PM Are bi-specifics really going to have a role in indolent lymphomas?
03:45 PM – 04:00 PM Sequencing of treatments in 2L+ setting for follicular lymphoma
04:00 PM – 04:15 PM Updates in treatment of mantle cell lymphoma - Krish Patel, MD
04:15 PM – 05:00 PM Q & A and Case-Based Panel Discussion - Michael Byrne, MD
05:00 PM – 06:00 PM Raise a Toast for Women in Hematology
**This is a non-CME activity**
DAY 3 – Sunday, October 13, 2024
07:00 AM – 08:00 AM Registration, Exhibits, & Socialize
07:00 AM – 08:15 AM Abstract Session *This is a non-CME Activity*
08:15 AM – 08:45 AM (Keynote)
08:45 AM – 10:00 AM Session 7 - CML/MPN
Chairs: Naveen Pemmaraju, MD
08:45 AM – 09:00 AM Incorporating novel JAKi and other therapies in MF management - Raajit Rampal, MD, PhD
09:00 AM – 09:15 AM Unanswered questions in CML in 2024 - Fadi Haddad, MD
09:15 AM – 09:30 AM Advanced MPN: Unanswered questions - Anand Patel, MD
09:30 AM – 10:15 AM Q & A and Case-Based Discussion - Ashwin Kishtagari, MD; Srinivas Tantravahi, MBBS, MRCP
10:15 AM – 10:30 AM Break & Exhibits
10:30 AM – 12:00 PM Session 8 - Multiple Myeloma - R/R
Chairs: Melissa Alsina, MD
10:30 AM – 10:45 AM Management of early relapses in myeloma-choosing the right combination - Melissa Alsina, MD
10:45 AM – 11:00 AM Integrating immunotherapies into the treatment of relapsed MM – CART, ADC, and bispecifics - Krina Patel, MD, MSc
11:00 AM – 11:15 AM Non-immune approaches for advanced myeloma
11:15 AM – 12:00 PM Q & A and Case- Based Discussion - Melissa Alsina, MD; Minoo Battiwalla, MD; Shaji Kumar, MD
12:00 PM Adjourn
FACULTY INFORMATION COMING SOON
Shaji Kumar, MD
Navneet Majhail, MD, MS, FASTCT
Sairah Ahmed, MD
Shaji Kumar, MD
Sairah Ahmed, MD
Bhagirathbhai Dholaria, MD
Fadi Haddad
Marina Konopleva, MD, PhD
Anand Patel, Assistant Professor of Medicine; Medical Director, Inpatient Leukemia Service
Krish Patel, MD
Somedeb Ball, Assistant Professor of Medicine, Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN
Michael Byrne, DO
Available Credit
- 12.50 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 12.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 12.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 12.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 12.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 12.50 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:
Link to register as an additional rep of a sponsoring company: https://education.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.